Flow headset image

Medical device company Flow, creators of the first and only medically approved treatment for depression of its kind in Europe, has raised £1.2 million in an investment round led by Khosla Ventures to tackle the world’s most urgent mental health challenges.

The investment will be used to support Flow’s European rollout, introduce Flow to healthcare clinics, and fund clinical studies.

Flow is a physical and behavioural, at-home treatment for depression which comprises a portable brain stimulation headset and therapy app. It combines clinical psychology, neuroscience and innovative technology including machine learning.

Classified as a Class IIa medical device, Flow launched in June 2019 in the UK and Sweden.

Randomised controlled trials published in the New England Journal of Medicine and the British Journal of Psychiatry showed that brain stimulation, of the type used in the Flow headset, had a similar impact to antidepressants but with fewer and less-severe side effects.

According to NHS England, in the UK, nearly one in four adults are affected by a mental illness. The Office for National Statistics also notes that suicide is the most common cause of death for men aged 20-49 years in England and Wales.

One in three work sickness notes handed out by GPs are for mental health reasons, including depression, says the NHS.

People diagnosed with depression often have lower neural activity in their left frontal lobe, the part of the brain controlling important cognitive skills including emotional expression. The Flow headset uses transcranial direct current stimulation (tDCS), a form of neurostimulation that delivers constant, low direct current via electrodes on the head to stimulate and rebalance neural activity in this area.

The brain stimulation headset is used in combination with a therapy app. This educates users with videos about depression and advice on how to reduce symptoms using the latest expert knowledge from the fields of sleep, nutrition, fitness and meditation.

Flow is starting talks with the NHS to have its brain stimulation headset available on prescription.

Daniel Mansson, Clinical Psychologist and Co-Founder of Flow, said: “We’re increasing treatment choice and empowering people to self-manage their symptoms at home with an effective, personalised and non-pharmacological alternative. This has the potential to improve the standard of care, and reduce global healthcare costs.

“The Khosla Ventures investment will support the next stage of our journey as we cement our position as European leaders of brain stimulation treatment for depression.”

Over 7,000 healthcare professionals stay informed about the latest assistive technology with AT Today. Do you?
We respect your privacy